A phase II, multicenter study to investigate the safety and efficacy of atezolizumab monotherapy as a sequential therapy following chemoradiotherapy in patients with locally advanced unresectable esophageal cancer
Latest Information Update: 22 Feb 2023
At a glance
- Drugs Atezolizumab (Primary) ; Cisplatin; Fluorouracil
- Indications Adenocarcinoma; Oesophageal cancer; Squamous cell cancer
- Focus Proof of concept; Therapeutic Use
- Acronyms TENERGY
- 21 Jan 2023 Results investigating predictive biomarkers for confirmed CR , presented at the 2023 Gastrointestinal Cancers Symposium
- 13 Sep 2022 Primary endpoint has been met (Confirmed complete response rate by investigators assessment) , according to Results presented at the 47th European Society for Medical Oncology Congress
- 13 Sep 2022 Results presented at the 47th European Society for Medical Oncology Congress